Research updates, pipeline progress, and breakthroughs in AI-driven drug discovery.
Omic announces continued growth to 15 employees and accelerated plans to advance multiple pipeline programs toward clinical development.
Omic launches enterprise and individual access to its AI Scientist platform, enabling researchers anywhere to leverage PhD-level AI for drug discovery and scientific research.
Omic demonstrates that its Digital Patient platform can predict clinical trial outcomes with unprecedented accuracy, potentially transforming how drugs are developed.
Omic launches CVD-001, a cardiovascular program targeting lipoprotein(a) with a novel small molecule approach discovered through AI-driven multi-omics analysis.
Omic announces HEM-001, a novel small molecule program for sickle cell disease using AI-designed P-selectin inhibitors with improved properties over existing therapies.
Omic launches INF-001, an innovative program targeting the HIV latent reservoir with the goal of achieving functional cure through AI-discovered mechanisms.
Omic announces ONC-001, its first internal oncology program targeting immune checkpoint inhibitor resistance, with lead compounds discovered entirely by AI.
Omic unveils its AI Scientist platform—an autonomous AI system capable of conducting drug discovery research independently, from hypothesis generation to experimental design.
Omic announces profitability milestone and plans to expand its AI drug discovery platform, grow the team, and launch internal pipeline programs.
Omic unveils its Digital Patient platform, enabling pharmaceutical researchers to simulate drug responses in computational patient models before conducting clinical trials.
Omic's AI platform successfully identifies novel drug targets that are subsequently validated in experimental studies, demonstrating the power of computational target discovery.
Omic marks its first year with significant progress on its multi-omics AI platform, expanding the team and establishing foundational technology for drug discovery.
Omic launches with a mission to end disease by teaching AI the language of biology. The company aims to build computational systems that understand biology at the molecular level.
